Abstract
Single-cell RNA-sequencing (scRNA-seq) is a powerful technology to uncover cellular heterogeneity in tumor ecosystems. Due to differences in underlying gene load, direct comparison between patient samples is challenging, and this is further complicated by the sparsity of data matrices in scRNA-seq. Here, we present a factorization method called KINOMO (Kernel dIfferentiability correlation-based NOn-negative Matrix factorization algorithm using Kullback-Leibler divergence loss Optimization). This tool uses quadratic approximation approach for error correction and an iterative multiplicative approach, which improves the quality assessment of NMF-identified factorization, while mitigating biases introduced by inter-patient genomic variability. We benchmarked this new approach against nine different methods across 15 scRNA-seq experiments and find that KINOMO outperforms prior methods when evaluated with an adjusted Rand index (ARI), ranging 0.82-0.91 compared to 0.68-0.77. Thus, KINOMO provides an improved approach for determining coherent transcriptional programs (and meta-programs) from scRNA-seq data of cancer tissues, enabling comparison of patients with variable genomic backgrounds.
Classification Physical Sciences (Applied Mathematics; Biophysics and Computational Biology), Biological Sciences (Applied Biological Sciences; Biophysics and Computational Biology; Medical Sciences; Systems Biology.).
Significance Statement Identification of shared or distinct cell programs in single-cell RNA-seq data of patient cancer cells is challenging due to underlying variability of gene load which determines transcriptional output. We developed an analytical approach to define transcriptional variability more accurately across patients and therefore enable comparison of program expression despite inherent genetic heterogeneity. Thus, this method overcomes challenges not adequately addressed by other methods broadly used for the analysis of single-cell genomics data.
Competing Interest Statement
The authors have declared no competing interest.